노바티스(NVS) 2026년 3분기 실적, 완만한 고평가 속 배당 지속가능성 부각

Novartis AG released its financial results for the third quarter of 2026, showcasing robust operational performance that surpassed Wall Street expectations. The pharmaceutical giant delivered a Non-GAAP earnings per share of $2.46, beating consensus estimates by a notable margin of $0.22. Revenues also showed solid growth, driven by strong demand across key therapeutic portfolios and efficient cost management. Analysts highlighted the strong cash flow generation, which reinforces the long-term sustainability of the company's dividend payouts. Despite the positive earnings report, some market observers note that shares appear modestly overvalued based on traditional valuation metrics. Investors continue to weigh the company's steady pharmaceutical pipeline against current macroeconomic pressures in the healthcare sector.